Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Cash (2020 - 2025)

Barinthus Biotherapeutics' Change in Cash history spans 6 years, with the latest figure at -$3.8 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 160.69% year-over-year to -$3.8 million; the TTM value through Dec 2025 reached -$40.5 million, down 36.57%, while the annual FY2025 figure was -$40.5 million, 36.57% down from the prior year.
  • Change in Cash reached -$3.8 million in Q4 2025 per BRNS's latest filing, up from -$12.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $112.7 million in Q1 2021 to a low of -$19.8 million in Q4 2021.
  • Average Change in Cash over 5 years is $1.4 million, with a median of -$11.7 million recorded in 2024.
  • Peak YoY movement for Change in Cash: skyrocketed 7672.02% in 2021, then plummeted 296.43% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$19.8 million in 2021, then surged by 71.14% to -$5.7 million in 2022, then tumbled by 218.57% to -$18.2 million in 2023, then soared by 134.57% to $6.3 million in 2024, then crashed by 160.69% to -$3.8 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Change in Cash are -$3.8 million (Q4 2025), -$12.1 million (Q3 2025), and -$12.8 million (Q2 2025).